Cargando…
(18)F-flutemetamol positron emission tomography in cardiac amyloidosis
PURPOSE: Bone-tracer scintigraphy has an established role in diagnosis of cardiac amyloidosis (CA) as it detects transthyretin amyloidosis (ATTR). Positron emission tomography (PET) with amyloid tracers has shown high sensitivity for detection of both ATTR and light-chain (AL) CA. We aimed to invest...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993783/ https://www.ncbi.nlm.nih.gov/pubmed/33025472 http://dx.doi.org/10.1007/s12350-020-02363-2 |
_version_ | 1784683973943754752 |
---|---|
author | Papathanasiou, Maria Kessler, Lukas Carpinteiro, Alexander Hagenacker, Tim Nensa, Felix Umutlu, Lale Forsting, Michael Brainman, Alexandra Kleinschnitz, Christoph Antoch, Gerald Dührsen, Ulrich Schlosser, Thomas-Wilfried Herrmann, Ken Rassaf, Tienush Luedike, Peter Rischpler, Christoph |
author_facet | Papathanasiou, Maria Kessler, Lukas Carpinteiro, Alexander Hagenacker, Tim Nensa, Felix Umutlu, Lale Forsting, Michael Brainman, Alexandra Kleinschnitz, Christoph Antoch, Gerald Dührsen, Ulrich Schlosser, Thomas-Wilfried Herrmann, Ken Rassaf, Tienush Luedike, Peter Rischpler, Christoph |
author_sort | Papathanasiou, Maria |
collection | PubMed |
description | PURPOSE: Bone-tracer scintigraphy has an established role in diagnosis of cardiac amyloidosis (CA) as it detects transthyretin amyloidosis (ATTR). Positron emission tomography (PET) with amyloid tracers has shown high sensitivity for detection of both ATTR and light-chain (AL) CA. We aimed to investigate the accuracy of (18)F-flutemetamol in CA. METHODS: We enrolled patients with CA or non-amyloid heart failure (NA-HF), who underwent cardiac (18)F-flutemetamol PET/MRI or PET/CT. Myocardial and blood pool standardized tracer uptake values (SUV) were estimated. Late gadolinium enhancement (LGE) and T1 mapping/ extracellular volume (ECV) estimation were performed. RESULTS: We included 17 patients (12 with CA, 5 with NA-HF). PET/MRI was conducted in 13 patients, while PET/CT was conducted in 4. LGE was detected in 8 of 9 CA patients. Global relaxation time and ECV were higher in CA (1448 vs. 1326, P = 0.02 and 58.9 vs. 33.7%, P = 0.006, respectively). Positive PET studies were demonstrated in 2 of 12 patients with CA (AL and ATTR). Maximal and mean SUV did not differ between groups (2.21 vs. 1.69, P = 0.18 and 1.73 vs. 1.30, P = 0.13). CONCLUSION: Although protein-independent binding is supported by our results, the diagnostic yield of PET was low. We demonstrate here for the first time the low sensitivity of PET for CA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12350-020-02363-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-8993783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-89937832022-04-22 (18)F-flutemetamol positron emission tomography in cardiac amyloidosis Papathanasiou, Maria Kessler, Lukas Carpinteiro, Alexander Hagenacker, Tim Nensa, Felix Umutlu, Lale Forsting, Michael Brainman, Alexandra Kleinschnitz, Christoph Antoch, Gerald Dührsen, Ulrich Schlosser, Thomas-Wilfried Herrmann, Ken Rassaf, Tienush Luedike, Peter Rischpler, Christoph J Nucl Cardiol Original Article PURPOSE: Bone-tracer scintigraphy has an established role in diagnosis of cardiac amyloidosis (CA) as it detects transthyretin amyloidosis (ATTR). Positron emission tomography (PET) with amyloid tracers has shown high sensitivity for detection of both ATTR and light-chain (AL) CA. We aimed to investigate the accuracy of (18)F-flutemetamol in CA. METHODS: We enrolled patients with CA or non-amyloid heart failure (NA-HF), who underwent cardiac (18)F-flutemetamol PET/MRI or PET/CT. Myocardial and blood pool standardized tracer uptake values (SUV) were estimated. Late gadolinium enhancement (LGE) and T1 mapping/ extracellular volume (ECV) estimation were performed. RESULTS: We included 17 patients (12 with CA, 5 with NA-HF). PET/MRI was conducted in 13 patients, while PET/CT was conducted in 4. LGE was detected in 8 of 9 CA patients. Global relaxation time and ECV were higher in CA (1448 vs. 1326, P = 0.02 and 58.9 vs. 33.7%, P = 0.006, respectively). Positive PET studies were demonstrated in 2 of 12 patients with CA (AL and ATTR). Maximal and mean SUV did not differ between groups (2.21 vs. 1.69, P = 0.18 and 1.73 vs. 1.30, P = 0.13). CONCLUSION: Although protein-independent binding is supported by our results, the diagnostic yield of PET was low. We demonstrate here for the first time the low sensitivity of PET for CA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12350-020-02363-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-10-06 2022 /pmc/articles/PMC8993783/ /pubmed/33025472 http://dx.doi.org/10.1007/s12350-020-02363-2 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Papathanasiou, Maria Kessler, Lukas Carpinteiro, Alexander Hagenacker, Tim Nensa, Felix Umutlu, Lale Forsting, Michael Brainman, Alexandra Kleinschnitz, Christoph Antoch, Gerald Dührsen, Ulrich Schlosser, Thomas-Wilfried Herrmann, Ken Rassaf, Tienush Luedike, Peter Rischpler, Christoph (18)F-flutemetamol positron emission tomography in cardiac amyloidosis |
title | (18)F-flutemetamol positron emission tomography in cardiac amyloidosis |
title_full | (18)F-flutemetamol positron emission tomography in cardiac amyloidosis |
title_fullStr | (18)F-flutemetamol positron emission tomography in cardiac amyloidosis |
title_full_unstemmed | (18)F-flutemetamol positron emission tomography in cardiac amyloidosis |
title_short | (18)F-flutemetamol positron emission tomography in cardiac amyloidosis |
title_sort | (18)f-flutemetamol positron emission tomography in cardiac amyloidosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993783/ https://www.ncbi.nlm.nih.gov/pubmed/33025472 http://dx.doi.org/10.1007/s12350-020-02363-2 |
work_keys_str_mv | AT papathanasioumaria 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT kesslerlukas 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT carpinteiroalexander 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT hagenackertim 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT nensafelix 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT umutlulale 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT forstingmichael 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT brainmanalexandra 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT kleinschnitzchristoph 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT antochgerald 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT duhrsenulrich 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT schlosserthomaswilfried 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT herrmannken 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT rassaftienush 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT luedikepeter 18fflutemetamolpositronemissiontomographyincardiacamyloidosis AT rischplerchristoph 18fflutemetamolpositronemissiontomographyincardiacamyloidosis |